Lv11
80 积分 2026-03-23 加入
Targeting IL-23 for IBD: Rationale and Progress to Date
3小时前
已完结
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
4个月前
已完结
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites
4个月前
已完结
Vitiligo
6个月前
已完结
皖公网安备34019202002308
